NYSE:ABT - Abbott Laboratories Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$62.14 -0.20 (-0.32 %)
(As of 06/20/2018 04:00 PM ET)
Previous Close$62.34
Today's Range$62.04 - $62.4950
52-Week Range$47.83 - $64.60
Volume5.12 million shs
Average Volume6.49 million shs
Market Capitalization$110.14 billion
P/E Ratio24.86
Dividend Yield1.78%
Beta1.51
Abbott Laboratories logoAbbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraines; and anti-infective clarithromycin, as well as provides influenza vaccine and products that regulate physiological rhythm of the colon. Its Diagnostic Products segment offers core laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automates the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detects and measures infectious agents; cartridges for blood analysis; benchtop systems and rapid tests in the areas of infectious diseases; molecular point-of-care test systems for influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test systems, as well as remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The company's Nutritional Products segment provides pediatric and adult nutritional products. Its Cardiovascular and Neuromodulation Products segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company also provides blood and flash glucose monitoring systems, including test strips, sensors, data management decision software, and accessories for people with diabetes. The company was founded in 1888 and is headquartered in Abbott Park, Illinois.

Receive ABT News and Ratings via Email

Sign-up to receive the latest news and ratings for ABT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNYSE:ABT
CUSIP00282410
Phone224-667-6100

Debt

Debt-to-Equity Ratio0.67
Current Ratio1.66
Quick Ratio1.24

Price-To-Earnings

Trailing P/E Ratio24.86
Forward P/E Ratio21.73
P/E Growth1.81

Sales & Book Value

Annual Sales$27.39 billion
Price / Sales3.98
Cash Flow$4.7363 per share
Price / Cash13.12
Book Value$17.87 per share
Price / Book3.48

Profitability

EPS (Most Recent Fiscal Year)$2.50
Net Income$477 million
Net Margins1.67%
Return on Equity14.54%
Return on Assets6.34%

Miscellaneous

Employees99,000
Outstanding Shares1,753,190,000

Abbott Laboratories (NYSE:ABT) Frequently Asked Questions

What is Abbott Laboratories' stock symbol?

Abbott Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABT."

How often does Abbott Laboratories pay dividends? What is the dividend yield for Abbott Laboratories?

Abbott Laboratories declared a quarterly dividend on Friday, June 8th. Investors of record on Friday, July 13th will be paid a dividend of $0.28 per share on Wednesday, August 15th. This represents a $1.12 annualized dividend and a yield of 1.80%. The ex-dividend date of this dividend is Thursday, July 12th. View Abbott Laboratories' Dividend History.

How were Abbott Laboratories' earnings last quarter?

Abbott Laboratories (NYSE:ABT) posted its earnings results on Wednesday, April, 18th. The healthcare product maker reported $0.59 earnings per share for the quarter, topping analysts' consensus estimates of $0.58 by $0.01. The healthcare product maker had revenue of $7.39 billion for the quarter, compared to analysts' expectations of $7.28 billion. Abbott Laboratories had a return on equity of 14.54% and a net margin of 1.67%. The company's revenue for the quarter was up 16.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.48 earnings per share. View Abbott Laboratories' Earnings History.

When is Abbott Laboratories' next earnings date?

Abbott Laboratories is scheduled to release their next quarterly earnings announcement on Thursday, July, 19th 2018. View Earnings Estimates for Abbott Laboratories.

What guidance has Abbott Laboratories issued on next quarter's earnings?

Abbott Laboratories issued an update on its FY18 earnings guidance on Wednesday, April, 18th. The company provided earnings per share (EPS) guidance of $2.80-2.90 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.86. Abbott Laboratories also updated its Q2 guidance to $0.70-0.72 EPS.

What price target have analysts set for ABT?

17 brokerages have issued 1-year price targets for Abbott Laboratories' shares. Their predictions range from $56.00 to $80.00. On average, they anticipate Abbott Laboratories' share price to reach $68.4375 in the next twelve months. View Analyst Ratings for Abbott Laboratories.

Who are some of Abbott Laboratories' key competitors?

Who are Abbott Laboratories' key executives?

Abbott Laboratories' management team includes the folowing people:
  • Mr. Miles D. White, Chairman & CEO (Age 63)
  • Mr. Brian B. Yoor, Exec. VP of Fin. & CFO (Age 48)
  • Mr. Hubert L. Allen, Exec. VP, Gen. Counsel & Sec. (Age 52)
  • Mr. Robert B. Ford, Exec. VP of Medical Devices (Age 44)
  • Mr. Daniel Gesua Sive Salvadori, Exec. VP of Nutritional Products (Age 39)

Has Abbott Laboratories been receiving favorable news coverage?

Press coverage about ABT stock has been trending positive on Wednesday, Accern Sentiment reports. Accern ranks the sentiment of press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Abbott Laboratories earned a media sentiment score of 0.43 on Accern's scale. They also assigned news coverage about the healthcare product maker an impact score of 48.26 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

Who are Abbott Laboratories' major shareholders?

Abbott Laboratories' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.39%), Massachusetts Financial Services Co. MA (2.28%), Northern Trust Corp (1.49%), Diamond Hill Capital Management Inc. (0.60%), FIL Ltd (0.54%) and Dimensional Fund Advisors LP (0.54%). Company insiders that own Abbott Laboratories stock include Alejandro D Wellisch, Brian J Blaser, Daniel Gesua Sive Salvadori, Daniel J Starks, Deepak S Nath, Heather L Mason, Hubert L Allen, Jaime Contreras, Jared Watkin, Joseph J Manning, Michael J Warmuth, Miles D White, Robert B Ford, Robert E Funck, Roger Bird, Sally E Blount, Sharon J Bracken and Stephen R Fussell. View Institutional Ownership Trends for Abbott Laboratories.

Which institutional investors are selling Abbott Laboratories stock?

ABT stock was sold by a variety of institutional investors in the last quarter, including Independent Franchise Partners LLP, Massachusetts Financial Services Co. MA, Flossbach Von Storch AG, Coho Partners Ltd., Swiss National Bank, American Century Companies Inc., Northern Trust Corp and Legal & General Group Plc. Company insiders that have sold Abbott Laboratories company stock in the last year include Alejandro D Wellisch, Brian J Blaser, Daniel Gesua Sive Salvadori, Hubert L Allen, Jaime Contreras, Jared Watkin, Miles D White, Roger Bird, Sharon J Bracken and Stephen R Fussell. View Insider Buying and Selling for Abbott Laboratories.

Which institutional investors are buying Abbott Laboratories stock?

ABT stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Montag & Caldwell LLC, Ceredex Value Advisors LLC, Eaton Vance Management, Summit Trail Advisors LLC, Mackay Shields LLC, CIBC World Markets Inc. and Franklin Resources Inc.. Company insiders that have bought Abbott Laboratories stock in the last two years include Brian J Blaser, Daniel J Starks, Miles D White, Robert B Ford and Sally E Blount. View Insider Buying and Selling for Abbott Laboratories.

How do I buy shares of Abbott Laboratories?

Shares of ABT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Abbott Laboratories' stock price today?

One share of ABT stock can currently be purchased for approximately $62.14.

How big of a company is Abbott Laboratories?

Abbott Laboratories has a market capitalization of $110.14 billion and generates $27.39 billion in revenue each year. The healthcare product maker earns $477 million in net income (profit) each year or $2.50 on an earnings per share basis. Abbott Laboratories employs 99,000 workers across the globe.

How can I contact Abbott Laboratories?

Abbott Laboratories' mailing address is 100 ABBOTT PARK ROAD D-322 AP6D, ABBOTT PARK IL, 60064. The healthcare product maker can be reached via phone at 224-667-6100.


MarketBeat Community Rating for Abbott Laboratories (ABT)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  645 (Vote Outperform)
Underperform Votes:  496 (Vote Underperform)
Total Votes:  1,141
MarketBeat's community ratings are surveys of what our community members think about Abbott Laboratories and other stocks. Vote "Outperform" if you believe ABT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.